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Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires 
monitoring of international normalised ratio (INR). We evaluated the agreement between two 
INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic 
range (TTR), using data from a global population of patients with newly diagnosed non-
valvular AF, the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-
AF). Among 17,168 patients with 1-year follow-up data available at the time of the analysis, 
8445 received VKA therapy (±antiplatelet therapy) at enrolment, and of these patients, 5066 
with ≥3 INR readings and for whom FIR and TTR could both be calculated were included in 
the analysis. In total, 70,905 INRs were analysed. At the patient level, TTR showed higher 
values than FIR (mean, 56.0% vs 49.8%; median, 59.7% vs 50.0%). Although patient-level 
FIR and TTR values were highly correlated (Pearson correlation coefficient [95% confidence 
interval; CI], 0.860 [0.852 to 0.867]), estimates from individuals showed widespread 
disagreement and variability (Lin’s concordance coefficient [95% CI], 0.829 [0.821 to 0.837]). 
The difference between FIR and TTR explained 17.4% of the total variability of 
measurements. These results suggest that FIR and TTR are not equivalent and cannot be 
used interchangeably. 
 
Keywords: atrial fibrillation, frequency in range, international normalised ratio, time in 
therapeutic range, vitamin K antagonists 
  































































Vitamin K antagonists (VKAs) such as warfarin are effective in reducing the risk of stroke 
and thromboembolism in patients with atrial fibrillation (AF) (Hart, et al 2007). It is well known 
that quality of VKA control is related to clinical outcome. The optimal international normalised 
ratio (INR) range is 2.0–3.0, as levels below 2.0 and above 3.5–4.0 are associated with 
increased risk of ischaemic stroke and intracranial haemorrhage, respectively (Hylek and 
Singer 1994, Hylek, et al 1996, Singer, et al 2009). 
The two most commonly reported audit parameters for INR control are frequency in range 
(FIR) – also known as proportion of INRs in the therapeutic range and number of tests in 
range – and the proportion of time in the therapeutic INR range (TTR) (Rosendaal, et al 
1993). TTR is a relatively difficult measure to calculate, requiring computer software, whilst 
FIR, certainly at an individual patient level, is much easier to calculate and can effectively be 
done manually. Indeed, the National Institute for Health and Care Excellence (NICE) 
recommends using ‘a validated method of measurement such as the Rosendaal method for 
computer-assisted dosing or proportion of tests in range for manual dosing’, whilst also using 
TTR of <65% as an indicator for poor anticoagulation control (NICE 2014). The European 
Society of Cardiology recommends a target TTR of at least 70% (Camm, et al 2012) and the 
Asia Pacific Heart Rhythm Society recommends a TTR of at least 60% (Ogawa, et al 2013) 
for optimal VKA control. 
This paper aims to elucidate the agreement between these two measures at an individual 
patient level using the largest INR dataset to date, from the Global Anticoagulant Registry in 
the FIELD–Atrial Fibrillation (GARFIELD-AF), a large contemporary prospective cohort study 
of patients newly diagnosed with non-valvular AF. We have chosen to compare TTR and FIR 
as these are reported in the majority of studies (Connolly, et al 2008, Fitzmaurice, et al 2000, 
Fitzmaurice, et al 2003, Franke, et al 2008, Singer, et al 2013, Van Spall, et al 2012, White, 




GARFIELD-AF is an ongoing worldwide observational registry of adults with a new diagnosis 
of non-valvular AF (Kakkar, et al 2012). Patients are being enrolled consecutively in five 
sequential cohorts. The use of antithrombotic therapies is at the discretion of study 
investigators. A site selection process was employed to ensure proportional 
representation of the spectrum of care settings in each country. First, the national 
coordinating investigator (NCI) identified the care settings they believed most 
accurately represented the management of patients with AF in their country. Then, 
from a list (sampling frame) of sites from various database searches that reflected the 






























































care settings in the country, the contract research organisation (CRO) contacted a 
random (ie, lack of selection of sites based on specific criteria rather than using 
random sampling) sample of sites for each care setting from the list, in accordance 
with the distribution specified by the NCI. A few sites were ‘selected’ by the CRO or 
NCI as replacement sites when sites dropped out or when we had exhausted the list 
and were still short of the required number of sites in a given country. This was very 
infrequent and only occurred in three countries. This article reports data for prospective 
patients enrolled from March 2010 to June 2013. 
 
Ethics statement 
Independent ethics committee and hospital-based institutional review board approvals were 
obtained, as necessary, for the registry protocol. The registry is being conducted in 
accordance with the principles of the Declaration of Helsinki. All patients provided written 
informed consent to participate. 
 
Data collection 
Data on consecutive patients were collected using an electronic case report form (eCRF) 
and captured by trained data abstractors. The eCRF was designed by Dendrite Clinical 
Systems Ltd (Henley-on-Thames, UK) and the Thrombosis Research Institute (London, UK) 
is responsible for data management. Source data verification (SDV) is regularly 
undertaken in the GARFIELD-AF study by monitoring 20% of the eCRF against source 
data. In the latest phase of SDV, the eCRF matched patient records 95.5% of the time. 
Data for the analysis in this report were extracted from the GARFIELD-AF study database on 
30 June 2014.   
 
VKA control: inclusion and exclusion criteria 
INR readings during the first year of follow-up were analysed. Patients on VKA 
treatment at enrolment contributed to the analysis from enrolment to the date of 
discontinuation of VKA or to the last date of follow-up in the study.  
The frequency of INR measurements is not mandated in the study. Patients on VKA 
treatment at enrolment but with fewer than three readings during the follow-up were 
excluded from the analysis. All INR readings after discontinuation of VKA were 
excluded even if the patient resumed VKA therapy. To exclude artifacts, INR readings 


































































Calculation of FIR and TTR 
The target range of INR for this study was 2.0–3.0, based on the recommendations 
from international guidelines (Camm, et al 2012, January, et al 2014). 
Patient-level FIR was calculated as the percentage of the total INR readings that were in 
range for each patient. 
Patient-level TTR was estimated by assigning INR values to each day between consecutive 
INR readings by linear interpolation, as described by Rosendaal et al (1993). TTR was 
estimated between two consecutive INR readings only if the interval did not exceed 90 days, 
based on the NICE-recommended INR testing interval of up to 12 weeks when values 
are stable (NICE 2015). If a patient had at least three INR readings and one or more of the 
intervals between readings exceeded 90 days, the remaining intervals were used to 
calculate TTR for the patient. 
 
Statistical analysis 
Patient-level FIR and TTR were compared using the Pearson correlation coefficient 
(Pearson 1896) and Lin’s concordance coefficient for agreement (Lin 1989, Lin 2000). The 
Pearson correlation coefficient measures the linear association between two continuous 
variables. Lin’s concordance coefficient for agreement combines measures of both precision 
and accuracy to determine how far the observed data deviate from the line of perfect 
concordance. 
We also estimated a variance component model to model the dependence between FIR and 
TTR for the same patient, by splitting the total variance of INR quality control measurements 
into two components: between-patient variance and within-patient (or residual) variance. The 
within-patient variability is due to the disagreement between FIR and TTR. The within-patient 
variability would be zero if FIR and TTR agreed perfectly. Lin’s concordance coefficient can 
be viewed as an intraclass coefficient estimated through variance components (Carrasco 
and Jover 2003). 
We also studied whether the number of INR readings affected the agreement between FIR 
and TTR, by plotting Lin’s concordance coefficient against the number of INR readings. 
A sensitivity analysis was performed by repeating all analyses except the variance 
component model and the analysis of the effect of number of INR readings on the 
agreement between FIR and TTR, but excluding INR readings in the first 90 days of VKA 
treatment. 
Analyses were performed using SAS statistical software, release 9.4 (SAS Institute, Cary, 
NC, USA) and Stata statistical software, version 13.1 (StataCorp, College Station, TX, USA). 
 































































Baseline characteristics of patients 
Overall, 17,168 prospective patients enrolled into GARFIELD-AF from March 2010 to June 
2013 had 1-year follow-up data available at the time of the analysis. Among these patients, 
8445 were on VKA therapy (with or without antiplatelet therapy) at enrolment, and of these 
patients, 5066 with at least three INR readings and for whom FIR and TTR could both be 
calculated were included in the analysis. The majority of these patients received warfarin 
(62.3%), followed by acenocoumarol (22.3%) and phenprocoumon (9.4%); 2.6% 
received other types of VKA and 3.4% received unknown VKAs. Of the patients, 963 
(19.0%) had 3–5 INR readings and 4103 (81.0%) had ≥6 INR readings. The mean age of 
these patients was 71.2 years and 43.9% were women (Table I). The mean CHA2DS2-VASc 
score was 3.4. 
 
INR readings 
A total of 70,905 INR readings were analysed. At the population level, the mean INR value 
was 2.4 and the median was 2.3 (Table II). Slightly more than half of the INR readings 
(51.8%) were in the therapeutic range (2.0–3.0) and of the remainder, a greater proportion 
were under the therapeutic range than above the range (31.2% and 17.0%, respectively; 
Table II and Fig 1). 
 
FIR and TTR 
Overall, TTR values were higher than FIR values at the patient level. The mean TTR and 
FIR were 56.0% and 49.8%, respectively, and the median TTR and FIR were 59.7% and 
50.0%, respectively (Table II). Using equal-sized intervals for histograms of patient-level FIR 
and TTR, the distribution of FIR showed greater variation between consecutive quantiles 
than TTR (Fig 2).  
FIR and TTR showed high correlation (Fig 3), with a Pearson correlation coefficient of 0.860 
(95% confidence interval [CI]: 0.852 to 0.867). However, concordance was poor according to 
McBride criteria (McBride 2005), with clear deviation from the line of perfect concordance 
(Fig 3). Lin’s concordance coefficient was 0.829 (95% CI: 0.821 to 0.837). 
In the variance component model, between-patient and within-patient variability explained 
82.6% (between-patient variance = 542.0) and 17.4% (within-patient variance = 113.9), 
respectively, of the total variance. In other words, the disagreement between FIR and TTR 
was responsible for 17.4% of the total variance. 
Although, on average, FIR increased as TTR increased, in the group of patients with a TTR 
of 70–80%, 25% had an FIR of less than 57.1% (Fig 4). 






























































Analysis of the agreement between FIR and TTR by the number of INR readings showed 
that Lin’s concordance coefficient decreased as the number of readings increased (Fig 5). 
Lin’s concordance coefficient did not show good agreement between FIR and TTR for any 
number of INR readings, although it was highest between 6 and 12 readings, ie, a frequency 
of one INR test every 1–2 months. 
 
Sensitivity analysis 
We performed a sensitivity analysis by excluding INR readings in the first 90 days of VKA 
treatment, to evaluate the effect of excluding INR readings during the period when patients 
were settling into their therapy regimen. The distribution of INR readings (n=42,036) is 
shown in Table III. The median was the same as that from the main analysis (2.3) but the 
mean was slightly higher (2.5 vs 2.4). The percentage of INR readings in the therapeutic 
range at the population level was higher than in the main analysis (56.6% vs 51.8%, 
respectively). 
The distribution of patient-level FIR and TTR is shown in Fig 6. The mean patient-level FIR 
and TTR were higher than those from the main analysis (FIR, 55.4% vs 49.8%; TTR, 60.3% 
vs 56.0%). 
Pearson and Lin’s coefficients (Pearson, 0.875 [95% CI: 0.867 to 0.882]; Lin, 0.858 [0.850 to 
0.865]) were similar to those from the main analysis (Pearson, 0.860 [0.852 to 0.867]; Lin, 
0.829 [0.821 to 0.837]). 
 































































FIR and TTR are two commonly used parameters for assessing quality of VKA control. FIR 
is based on a discrete number of visits, whereas TTR is estimated for each day of the follow-
up period; however, FIR has the advantage of being simpler to calculate. We evaluated the 
agreement between these two measures at an individual patient level. Our analysis showed 
that FIR was not equivalent to TTR, with TTR values being higher than FIR values overall. 
Although the two parameters were highly correlated, there was widespread disagreement 
and variability between them. In the variance component model, the within-patient variability, 
which is due to differences between FIR and TTR, was high enough to have clinical 
relevance. In general, FIR increased as TTR increased; however, the great variability 
between the measures meant that, for example, in a subset of patients with good VKA 
control according to TTR (70–80%), a quarter had an FIR of less than 57%, which would 
indicate inadequate VKA control. These results suggest that clinical assessment of the 
quality of VKA control at the patient level may change considerably if FIR is used instead of 
TTR. 
The agreement between FIR and TTR decreased as the number of INR readings increased, 
and was greatest between 6 and 12 INR readings (ie, an INR test every 1–2 months). We 
speculate that the highest numbers of INR tests were done on patients with very unstable 
INR, for whom the linear interpolation assumption in the estimation of TTR may not hold. 
The mean patient-level FIR and TTR were higher in the sensitivity analysis (excluding INR 
readings in the first 90 days of VKA treatment) than in the main analysis, although the 
degree of correlation and concordance between FIR and TTR was similar to that found in the 
main analysis. This suggests that for meaningful results, INR readings in the early period of 
VKA therapy, when patients are settling into the therapy regimen, should be treated with 
caution in analyses. 
A study by Schmitt et al (2003) compared three methods for assessing quality of VKA 
control, FIR, TTR and cross-section of the files, and showed that TTR gave a significantly 
shorter mean time in therapeutic range versus each of the other methods over six 2-month 
intervals. Similar differences were found when analyses were performed for 3-month and 6-
month time intervals. The study was a retrospective analysis of 633 patients managed by a 
university hospital-based, pharmacist-managed anticoagulation clinic in the USA, with 1 year 
of follow-up. Recently, a retrospective cohort study of 377 VKA-treated outpatients attending 
the cardiology anticoagulation clinic of a Portuguese hospital showed that FIR and TTR were 
significantly correlated but not equivalent, due to high variability between the parameters 
(Caldeira, et al 2015). Our study extends these findings by analysing data from an 
international cohort of 8445 prospective patients. 






























































Overall, 60% (5066/8445) of patients on VKA with at least three INR readings and for 
whom FIR and TTR could both be calculated were included in the analysis. However, 
because the frequency of INR testing is not mandated in this real-world study, a 
significant proportion of patients had fewer than three INR readings and this is clearly 
a limitation of the study. Based on clinical input, it was felt that a criterion for the 
minimum number of readings required over the 1-year period of follow-up should be 
at least three. The best agreement between FIR and TTR was found between 6 and 12 
readings, ie, a frequency of one INR test every 1–2 months; it should be noted that 
81% (4103/5066) of patients included in the analyses had at least six INR readings 
over the 1-year follow-up period. Although the target INR range used in this study is 
based on recommended international guidelines (Camm, et al 2012, January, et al 
2014), we recognise that investigators in each country may have been guided by 
national guidelines that differ from this target range; for example, Japanese 
guidelines (J.C.S. Joint Working Group 2014). This represents a further limitation of 
this study. 
In conclusion, our data show that FIR and TTR are not equivalent and cannot be used 
interchangeably. FIR gives a lower value than TTR overall. It is not possible to conclude 
from our data that one measure is better than the other. However, we suggest that 
TTR is reported if only one INR audit parameter is reported, and that FIR is only used 
if it is not possible to calculate TTR. The reason is that TTR takes into account the 
time between INR readings and may also be a better proxy for clinical outcomes, as 
observed by Wan et al (2008). We also suggest that patients who are receiving warfarin (or 
any other VKA) are managed utilising computerised decision support systems, so that the 
generation of these data for both an individual and a population is straightforward.  
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Table I. Baseline characteristics in patients on vitamin K antagonist at enrolment with 
at least two INR readings and for whom both frequency in range and proportion of 
time in the therapeutic range could be calculated. 
Variable N=5066 
Age  
 Mean (SD), years  71.2 (10.2) 
Age group, n (%)  
 <65 y 1195 (23.6) 
 65–74 y 1752 (34.6) 
 ≥75 y 2119 (41.8) 
Gender, n (%)  
 Women 2223 (43.9) 
Race, n (%)  
 Caucasian 3761 (76.3) 
 Asian 860 (17.5) 
 Other 307 (6.2) 
 Unwilling to declare 138 
Smoking habits  
 Current smoker 420 (9.3) 
 Ex-smoker 1266 (27.9) 
 No 2850 (62.8) 
 Unknown 530 
CHA2DS2-VASc  
 Mean (SD) 3.4 (1.5) 
 Median (interquartile range) 3.0 (2.0–4.0) 
 0, n (%) 86 (1.7) 
 1, n (%) 422 (8.5) 
 2, n (%) 857 (17.3) 
 ≥3, n (%) 3589 (72.5) 
 Unknown 112 
INR, international normalised ratio; SD, standard deviation 
  






























































Table II. Distribution of INR readings, patient-level frequency in range and patient-
level proportion of time in the therapeutic range. 
 INR FIR TTR 
N 70,905 readings 5066 patients* 5066 patients* 
Median (IQR) 2.3 (1.9–2.8) 50.0 (33.3–66.7) 59.7 (38.6–76.2) 
Mean (SD) 2.4 (0.9) 49.8 (23.8) 56.0 (26.9) 
INR <2.0, n (%) 22,149 (31.2) - - 
INR 2.0–3.0, n (%) 36,676 (51.8) - - 
INR >3.0, n (%) 12,080 (17.0) - - 
FIR, frequency in range; INR, international normalised ratio; IQR, interquartile range; SD, 
standard deviation; TTR, proportion of time in the therapeutic range 
*The number of INR readings was the same for FIR and TTR but for TTR, intervals between 
INR readings that were >90 days were excluded 
  






























































Table III. Distribution of INR readings, patient-level frequency in range and patient-
level proportion of time in the therapeutic range, excluding readings in the first 90 
days of treatment. 
  INR FIR TTR 
N 42,036 readings 4191 patients 4191 patients 
Median (IQR) 2.3 (2.0–2.8) 58.3 (38.5–73.7) 64.3 (42.8–81.9) 
Mean (SD) 2.5 (0.8) 55.4 (25.6) 60.3 (27.7) 
INR <2.0, n (%) 10,878 (25.9%) - - 
INR 2.0–3.0, n (%) 23,771 (56.6%) - - 
INR >3.0, n (%) 7387 (17.6%) - - 
FIR, frequency in range; INR, international normalised ratio; IQR, interquartile range; SD, 
standard deviation; TTR, proportion of time in the therapeutic range 
  






























































Fig 1. Distribution of INR readings. 
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Fig 2. Distribution of patient-level frequency in range (A) and proportion of time in the 







INR, international normalised ratio






























































Fig 3. Concordance between patient-level frequency in range and proportion of time in 
the therapeutic range. The black line is the line of perfect concordance and the blue 
line is the line of regression. 
 
 
FIR, frequency in range; TTR, proportion of time in the therapeutic range 
  






























































Fig 4. Frequency in range by level of proportion of time in the therapeutic range at the 
patient level. 
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Fig 5. Agreement between frequency in range and time in the therapeutic range by 
number of INR readings. 
 
INR, international normalised ratio  






























































Fig 6. Distribution of patient-level frequency in range (A) and proportion of time in the 







INR, international normalised ratio 
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Fig 1. Distribution of INR readings. 
INR, international normalised ratio  
101x73mm (300 x 300 DPI)  
 
 

































































Fig 2. Distribution of patient-level frequency in range (A) and proportion of time in the therapeutic range 
(B). 
INR, international normalised ratio  
101x73mm (300 x 300 DPI)  
 
 


































































101x73mm (300 x 300 DPI)  
 
 

































































Fig 3. Concordance between patient-level frequency in range and proportion of time in the therapeutic 
range. The black line is the line of perfect concordance and the blue line is the line of regression. 
FIR, frequency in range; TTR, proportion of time in the therapeutic range  
101x73mm (300 x 300 DPI)  
 
 

































































Fig 4. Frequency in range by level of proportion of time in the therapeutic range at the patient level. 
FIR, frequency in range; TTR, proportion of time in the therapeutic range  
101x73mm (300 x 300 DPI)  
 
 

































































Fig 5. Agreement between frequency in range and time in the therapeutic range by number of INR readings. 
INR, international normalised ratio  
101x73mm (300 x 300 DPI)  
 
 

































































Fig 6. Distribution of patient-level frequency in range (A) and proportion of time in the therapeutic range 
(B), excluding INR readings in the first 90 days of treatment. 
INR, international normalised ratio  
101x73mm (300 x 300 DPI)  
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